GEN News Highlights: Nov 29, 2011

Expedeon, Protein Discovery Ink Merger Deal

(Page 1 of 1)

    Expedeon and Protein Discovery have decided to come together to create a supplier of products for protein research. The new Expedeon created under the merger agreement will have a portfolio of protein analysis and purification products.

    Protein Discovery, founded in 2001, develops and commercializes sample preparation products for protein analysis by mass spectrometry. Its flagship product is the Gelfree® 8100 Fractionation System. It partitions complex protein mixtures into user-selectable, liquid-phase molecular weight fractions. The company also has consumables like the FASP™ Protein Digestion kits and PPS Silent® Surfactant.

    Expedeon develops tools and reagents for protein discovery and analysis. Its products include solutions for protein separation, quantitation, visualization, purification, protection, and refolding. Its portfolio includes RunBlue® electrophoresis precast gels, InstantBlue® protein stain, and Nvoy™ protein stabilization products. It has offices in Cambridge, U.K., and San Diego, CA, and products are sold through a network of partners around the globe.

    The new entity will remain headquartered in Cambridge, U.K. "This transaction represents an important step toward our strategic goal of becoming a premier, global provider of innovative product solutions for protein analysis," says Heikki Lanckriet, founder and CEO of Expedeon, who will be CEO of the new company.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll